Omega-3 Fatty Acid Treatment in Multiple Sclerosis
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
Based on previous clinical studies indicating beneficial treatment effects of omega-3 fatty
acids in multiple sclerosis, and the increasing evidence of anti-inflammatory effects of
omega-3 fatty acids, this study aims to evaluate treatment effects of concentrated omega-3
fatty acids (Triomar™) in MS, both as monotherapy and in combination with standard
immunomodulatory therapy defined as interferon-beta 1a (Rebif™).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Haukeland University Hospital
Collaborators:
Amersham Health Pronova BioPharma Serono Nordic The Multiple Sclerosis National Competence Centre The Norwegian Multiple sclerosis Society